InPlay: ISTA Pharm reports 'positive', topline results from its Phase 2 clinical trial of BEPOSONE nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis Briefing.com07:30am EDT
GLYE best chart in last week....on low volume....upside has been steady/solid.....debate to 3
REPCF too a hit yesterday from 2.60 to 1.90....Reminder they are about to announce clinical results for their cure for baldness treatment today or tomorrow....Stay focused.
Recall XCLL daylong flexing / been discussing turnaround off of .40...
XcelMobility Concludes Exclusive Indonesian Supply Contract With ZTE Corp. Marketwire09:00am EDT
UGHS recent building off of .20...... UGHS.PKApr 300.260.00
University General Health System Announces Capital Raise of $3.8 Million Marketwire08:28am EDT
Winners And Losers In The Deadly Waters Of Biotech Investing at Seeking Alpha06:12am EDT
BioSolar to Select Contract Manufacturer for BioBacksheet Business Wire03:01am EDT
VELA remains rangebound in .02s but do recall pop on the news last week to upper .02s..... 023 close......Reminder on deal be low being quit upbeat for the company....getting ministry of china goahead in particular...
Patient for another eventual breakout as the deals take effect (ducks become more in a roll),...with revenue starting to snowball into 2012....
VelaTel Has Reached Key Milestones With VN Tech's Hydrogen Back Up Power Devices Marketwire08:00am EDT
Most Active Penny Stocks:
Recall discussion on MSLP constant back above .02
NEOM two wk pullback from .02...starting to flex........
Penny Stocks (Most Gained)SYMBLast%ChgVolume NKRN0.03172.7%19,500 CVBT0.2100.0%147,800 BLIBQ0.0392.3%79,200 ZYTC0.0566.7%15,000 CSDT0.0562.7%588,100
Momentum Stocks SYMBLast%ChgVolume LQMT0.4724.5%11,221,975 NEOM0.0114.2%34,701,680 NEON5.1112.3%642,872 MSLP0.029.2%17,008,123
Groupon CEO Schultz quits board. Groupon (GRPN) Chairman and CEO Howard Schultz and Accel Partners' Kevin Efrusy are stepping down from Groupon's (GRPN) board and will be replaced by Daniel Henry, CFO of American Express, and Deloitte Vice Chairman Robert Bass. The shakeup comes as Groupon looks to shore up investor confidence following the fiasco of its Q4 restatement. Opinion: Is Groupon now a buy?
Deepwater disaster still haunts BP's results. BP's (BP) closely watched clean replacement cost profit fell a more-than-expected 12.8% in Q1 to $4.8B even as revenue climbed 9.4% to $96.7B. A drop in production following asset sales as a result of the Gulf oil spill offset higher oil prices. Shares -3.5% premarket. Opinion: Deep drilling capability can help BP.
U.S. may issue floating notes. The Treasury could tomorrow provide details about its plans to start issuing floating-rate debt for the first time ever. However, Campbell Harvey, described by Bloomberg as the "father of Treasury floaters," warns that with interest rates at historic lows, floating-rate debt introduces risk and so should be avoided right now. Opinion: Trading strategies for long-term Treasuries.
Top Stock News
British panel slams Murdoch over phone hacking. A U.K. parliamentary committee has accused Rupert Murdoch of "willful blindness" over the depth of the phone hacking at News Corp.'s (NWS) U.K. newspapers and said he is "not a fit person" to manage a multinational corporation. In a scathing report, MPs also slammed the "huge failure of corporate governance at News Corp." Opinion: News Corp. shareholders might now win from a murdoch Loss
While Delta invests $250M to enter refining sector... Delta Air Lines (DAL) has confirmed it will purchase the Trainer refinery in Philadelphia from ConocoPhillips (COP) spinoff Phillips 66 as part of an attempt to cut its fuel expenses by $300M a year. The deal includes pipelines that transport the fuel to JFK, LaGuardia and other airports, and "strategic sourcing and marketing agreements" with BP (BP) and Phillips 66. Opinion: Friendly skies or turbulence ahead?
Goto www.greenbackers.com for more related on nanocaps
We caution investors to perform additional due diligence when considering positions in stocks listed in our bulletins.
Greenbackers.com is not and does not represent itself to be a registered investment advisor. Greenbackers.com does not receive compensation of any form, from companies it provides information on in it's newsletters, unless specifically stated. Under no circumstances at all, shall any representative of Greenbackers.com be held liable for any loss incurred as a result of an individual's decision to invest, based upon any information provided by Bulletins issued from Greenbackers or Data presented on the Greenbackers.com website. Please see disclaimer for more info.